Pharmacovigilance in Asia
Pipasha Biswas1,2★★ Corresponding author
- 1Symogen Limited, Bourne End, United Kingdom.
- 2Special Interest Network Consultation Committee for Drug Safety and Pharmacovigilance, Faculty of Pharmaceutical Medicine, Royal College of Physicians, London, UK.
Volume 4, Issue 4S · pp. S7–S8 · PUBLISHED 2013 · DOI: 10.4103/0976-500X.120941
ABSTRACT
An increase in drug safety concerns in recent years with some high profile drug withdrawals have led to raising the bar by various stakeholders more importantly by the regulatory authorities. The number of Adverse Drug Reactions (ADRs) reported have also resulted in an increase in the volume of data handled and to understand pharmacovigilance a high level of expertise is required to rapidly detect drug risks as well as to defend the product against an inappropriate removal. Proactive pharmacovigilance throughout the product life cycle is the way forward and the future direction for drug safety in Asia. It has been a constant challenge to standardize pharmacovigilance in Asia, in the context of clinical trials and post-marketing pharmacovigilance due to varied geaographical, cultural and medical practices in these regioon. While major advancements of the discipline of pharmacovigilance have taken place in the West, not much has been achieved in Asian countries, though several attempts have been taken. However, with more clinical trials and clinical research activity being conducted in the Asian continent, there is an immense need to understand and implement pharmacovigilance. For this to happen, the mind set of people working in regulatory agencies, the Pharmaceutical companies, prescribers and patients/consumers need to change.
KEYWORDS
REFERENCES
As publishedShowing references and in-text citations exactly as published.
Cite this article
SELECT FORMAT
Biswas, P. (2013). Pharmacovigilance in Asia. Journal of Pharmacology and Pharmacotherapeutics, 4(4S), S7–S8. https://doi.org/10.4103/0976-500X.120941